Fitch: Global Pharmaceutical Approvals Moderate as Patent Cliff Peaks

 Fitch: Global Pharmaceutical Approvals Moderate as Patent Cliff Peaks

CHICAGO--Fitch Ratings expects the Food and Drug Administration (FDA) will approve fewer novel drugs in 2012 as compared to 2011 while the industry faces several ongoing operational risks, according to a new report.

Fitch believes that the total of 30 new primary care and specialty medicines cleared for marketing in the U.S. during 2011 will be difficult to beat this year. Despite a strong first quarter with eight new molecular entities (NMEs) approved, the total of 14 new approvals in the first half of 2012 (1H'12) lags behind the 18 new approvals in the same period of 2011.

These trends come as the global pharmaceutical industry faces several risks over the course of 2012, including a historic zenith in the dollar amount of drug patent expirations. Four of the industry's once top-10 best-selling medications will have lost market exclusivity by the end of 3Q'12. Fitch anticipates little relief from the patent cliff this year, as key drug patents continue to lapse and the industry contends with 2011 losses.

Coupled with pressure from European austerity measures, Fitch-rated drug developers saw average weighted revenues fall modestly in the first quarter after adjusting for currency changes and consolidation activities within the past 12 months.

Fitch-covered pharmaceutical developers returned a total of $22.1 billion to shareholders in 1Q'12, comprising $15.3 billion in dividends and $6.8 billion of share buybacks. Fitch believes that share repurchases will exceed dividends as the year progresses.

The full report 'Global Pharmaceutical R&D Pipeline: First-Quarter 2012' is available at 'www.fitchratings.com.'

Additional information is available at 'www.fitchratings.com'.

Applicable Criteria and Related Research: Global Pharmceutical R&D Pipeline: First-Quarter 2012

http://www.fitchratings.com/creditdesk/reports/report_frame.cfm?rpt_id=683176

ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK: HTTP://FITCHRATINGS.COM/UNDERSTANDINGCREDITRATINGS. IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF CONDUCT' SECTION OF THIS SITE.
Contacts

Fitch Ratings
Michael Zbinovec, +1-312-368-3164
Fitch, Inc.
70 W. Madison Street
Chicago, IL 60602
[email protected]
or
Britta Holt, +00 44 20 3530 1335
[email protected]
or
Media Relations:
Brian Bertsch, New York, +1-212-908-0549
Email: [email protected]
 

Suggested Articles

IMV’s lead immunotherapy stopped ovarian cancer from getting worse in more than three-quarters of patients in a small phase 2 study.

The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test with Roche’s checkpoint inhibitor Tecentriq.

Bicycle will apply its discovery platform to multiple targets, putting itself in a position to pull in up to $1.7 billion in milestones.